These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 15701766

  • 21. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.
    Gales BJ, Bailey EK, Reed AN, Gales MA.
    Ann Pharmacother; 2010 Feb; 44(2):360-6. PubMed ID: 20086184
    [Abstract] [Full Text] [Related]

  • 22. Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials.
    McFarlane SI.
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1363-71. PubMed ID: 19900019
    [Abstract] [Full Text] [Related]

  • 23. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M.
    Am J Cardiol; 2007 Aug 06; 100(3A):38J-44J. PubMed ID: 17666197
    [Abstract] [Full Text] [Related]

  • 24. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM.
    Acta Diabetol; 2005 Apr 06; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [Abstract] [Full Text] [Related]

  • 25. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA, Molnar J, Arora RR.
    J Cardiovasc Pharmacol Ther; 2007 Sep 06; 12(3):192-204. PubMed ID: 17875946
    [Abstract] [Full Text] [Related]

  • 26. Do angiotensin II receptor blockers increase the risk of myocardial infarction?
    Verdecchia P, Angeli F, Gattobigio R, Reboldi GP.
    Eur Heart J; 2005 Nov 06; 26(22):2381-6. PubMed ID: 16081468
    [Abstract] [Full Text] [Related]

  • 27. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P.
    J Hypertens; 2008 Jul 06; 26(7):1282-9. PubMed ID: 18550998
    [Abstract] [Full Text] [Related]

  • 28. Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
    Pfeffer MA.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 06; 1(2 Suppl):S41-3. PubMed ID: 17199221
    [Abstract] [Full Text] [Related]

  • 29. Use of valsartan in post-myocardial infarction and heart failure patients.
    Liu PP, Maggioni A, Velazquez EJ.
    J Renin Angiotensin Aldosterone Syst; 2006 Jun 06; 7 Suppl 1():S19-22. PubMed ID: 16986231
    [Abstract] [Full Text] [Related]

  • 30. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
    Andraws R, Brown DL.
    Am J Cardiol; 2007 Apr 01; 99(7):1006-12. PubMed ID: 17398202
    [Abstract] [Full Text] [Related]

  • 31. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005 Apr 01; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

  • 32. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
    Kuti EL, Baker WL, White CM.
    Curr Med Res Opin; 2007 Jun 01; 23(6):1239-44. PubMed ID: 17559720
    [Abstract] [Full Text] [Related]

  • 33. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA.
    Am J Cardiol; 2007 Aug 06; 100(3A):45J-52J. PubMed ID: 17666198
    [Abstract] [Full Text] [Related]

  • 34. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX, Ye X, Lee KY, Dupclay L, Plauschinat C.
    Clin Ther; 2008 Aug 06; 30 Pt 2():2217-27. PubMed ID: 19281916
    [Abstract] [Full Text] [Related]

  • 35. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ.
    Prev Cardiol; 2008 Aug 06; 11(4):215-22. PubMed ID: 19476574
    [Abstract] [Full Text] [Related]

  • 36. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Aug 06; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 37. Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias.
    Garg S, Narula J, Marelli C, Cesario D.
    Am J Cardiol; 2006 Mar 15; 97(6):921-5. PubMed ID: 16516603
    [Abstract] [Full Text] [Related]

  • 38. [ACE inhibitor or ATII receptor blocker in heart failure and myocardial infarction?].
    Landmark K, Reikvam A.
    Tidsskr Nor Laegeforen; 2005 Jan 06; 125(1):38-40. PubMed ID: 15643463
    [Abstract] [Full Text] [Related]

  • 39. How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?
    Gustafsson F, Segura J, Ruilope LM.
    J Hypertens; 2010 Aug 06; 28(8):1595-8. PubMed ID: 20613629
    [Abstract] [Full Text] [Related]

  • 40. Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors.
    Krum H, Haas SJ, Eichhorn E, Ghali J, Gilbert E, Lechat P, Packer M, Roecker E, Verkenne P, Wedel H, Wikstrand J.
    Eur Heart J; 2005 Oct 06; 26(20):2154-8. PubMed ID: 16014644
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.